However, there is a lack of substantive evidence to suggest that periodic pharmacodynamic monitoring is useful in preventing or minimizing idiosyncratic ADRs. Given that the definition of an idiosyncratic ADR means that these reactions are unpredictable, periodic monitoring is subject to wide interpretation as to when and how often a patient should be monitored. The cost of such an intervention would almost certainly outweigh the benefits in most situations at this time. Dissemination of information is the most important, yet most conspicuously lacking, component of the current system. Idiosyncratic reactions will continue to occur.
Routine monitoring is unlikely to aid in avoiding ADRs.
Be aware of potential reactions by continuous review of the medical literature. Inform patients about likely initial symptoms of idiosyncratic ADRs. What to do until the FDA arrives. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. A retrospective review.